Hematopoiesis News 11.12 March 31, 2020 | |
| |
TOP STORYThe Evolutionary Dynamics and Fitness Landscape of Clonal Hematopoiesis Scientists showed that positive selection, not drift, was the major force shaping clonal hematopoiesis, provided bounds on the number of hematopoietic stem cells, and quantified the fitness advantages of key pathogenic variants, at single-nucleotide resolution, as well as the distribution of fitness effects within commonly mutated driver genes. [Science] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers demonstrated the requirement of the alternative polyadenylation (APA) regulator Pabpn1 for HSC function. They then determined the genome-wide APA landscape of HSCs and progenitors by performing low-input 3′ sequencing paired with bioinformatic pipelines. [Cell Stem Cell] Abstract | Graphical Abstract | Press Release Macrophages in C57BL/6 with Sirpahuman/human had an affinity for human CD47 significantly stronger than those with SirpaNOD/NOD, and did not show detectable phagocytosis against human hematopoietic stem cells. [Blood] Abstract Deterioration of Hematopoietic Autophagy Is Linked to Osteoporosis Scientists demonstrated that the deterioration of hematopoietic autophagy was coupled with osteoporosis in humans. With a conditional mouse model in which autophagy in the hematopoietic system was disrupted by deletion of the Atg7 gene, they showed that incapacitating hematopoietic autophagy caused bone loss and perturbed osteocyte homeostasis. [Aging Cell] Full Article Researchers report that up to 12-fold enhancement in the transduction efficiency of adeno-associated virus 6 (AAV6) vectors could be achieved in primary human HSCs with polyvinyl alcohol. [Mol Ther Nucleic Acids] Abstract | Full Article Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness In contrast to Dnmt3a-null HSCs, which possessed limitless self-renewal in vivo, Tet2-null HSCs unexpectedly exhausted at the same rate as control HSCs in serial transplantation assays despite an initial increase in self-renewal. [Stem Cell Reports] Full Article Targeted Gene Therapy into a Safe Harbor Site in Human Hematopoietic Progenitor Cells In human hematopoietic stem and progenitor CD34+ cells, the nucleofection process preserved the viability and clonogenic capacity of nucleofected cells, reaching up to 3.1% of specific integration of the transgene in colony forming cells when the SH6-TALEN was used, although no expression of the transgene could be found in these cells. [Gene Ther] Abstract GATA Factor-Mediated Gene Regulation in Human Erythropoiesis Scientists explored GATA-mediated transcriptional regulation through the integrative analysis of gene expression, chromatin modifications, and GATA factors’ binding in human multipotent hematopoietic stem/progenitor cells, early erythroid progenitors, and late precursors. [iScience] Abstract | Full Article | Graphical Abstract CLINICAL RESEARCHInvestigators analyzed the outcomes of 146 severe aplastic anemia patients who received a combination of haploidentical haematopoietic stem cell transplantation and an unrelated cord-blood unit between September 2011 and December 2017. [Bone Marrow Transplant] Abstract Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWSLineage Decision-Making within Normal Hematopoietic and Leukemic Stem Cells To produce the wide range of blood and immune cell types, hematopoietic stem cells can “choose” directly from the entire spectrum of blood cell fate-options. Affiliation to a single cell lineage can occur at the level of the hematopoietic stem cell and these cells are therefore a mixture of some pluripotent cells and many cells with lineage signatures. [Int J Mol Sci] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSTakeda Pharmaceutical Company Limited announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for the extension of the marketing authorization of ADCETRIS® and recommended its approval in combination with CHP as a treatment for adult patients with previously untreated systemic anaplastic large cell lymphoma. [Takeda Pharmaceutical Company Limited] Press Release Bristol Myers Squibb and bluebird bio, Inc. announced the submission of their BLA to the FDA for idecabtagene vicleucel, the companies’ lead investigational BCMA-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. [Bristol Myers Squibb (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSCull, Release or Bring Them Home: Coronavirus Crisis Forces Hard Decisions for Labs with Animals As universities scale back operations and scientists observe stay-at-home orders, many are struggling to protect their research and the animals that power it. [Nature News] Editorial Universities Issue Hiring Freezes in Response to COVID-19 Numerous universities have made announcements about the suspension of hiring, including Miami University of Ohio, Wright State University, Villanova University, the University of Nevada, Reno, Indiana University, and the University of Auckland in New Zealand, which cites the travel ban affecting Chinese students as one of the main causes of its freeze. [The Scientist] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Regenerative Medicine (Hannover Medical School) NEW Research Fellow – Cancer Biology (Dana Farber Cancer Institute) Postdoctoral Research Scientist – Diagnostic Tests (NHS Blood and Transplant) Scientist – Cancer Immunotherapy (Asgard Therapeutics and Lund University) Postdoctoral Fellow – Hematopoiesis Research (Harvard Medical School) Postdoctoral Researcher – Pediatric Oncology (Universitätsklinikum Carl Gustav Carus) Research Associate – Stem Cell and Gene Therapy Program (Fred Hutchinson Cancer Research Center) Postdoctoral Position – RNA Modifications, Hematopoiesis and Cancer (Lund University) Assistant/Associate Professor – Hematology & Oncology (UC Davis School of Medicine) Associate/Professor – Hematology & Oncology (UC Davis School of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|